Skip to content
Research/Stem Cell Therapy/Human Mesenchymal Stem Cells

Human Mesenchymal Stem Cells

Human Mesenchymal Stem Cells (hMSCs) are multipotent stromal cells that can differentiate into a variety of cell types, including bone, cartilage, and fat cells. They are primarily used in regenerative medicine due to their ability to repair and regenerate damaged tissues, making them significant for longevity and health optimization. Their immunomodulatory properties also contribute to their potential in treating inflammatory and autoimmune conditions.

Intelligence Profile

Clinical Applications

Human Mesenchymal Stem Cells (MSCs) are being investigated for various promising clinical applications due to their regenerative capabilities and immunomodulatory properties.

Diabetic Bone Regeneration

A study published in Regenerative Biomaterials highlights the use of Mn-Icariin-functionalized hydrogels with MSCs to promote bone regeneration in diabetic patients. This approach focuses on restoring redox balance and enhancing bone and blood vessel growth.

Post-COVID-19 Chronic Cough

Research in Frontiers in Medicine explores MSC-derived extracellular vesicles administered via nebulization for post-COVID-19 chronic cough. This pilot study indicates potential benefits in reducing persistent cough symptoms following COVID-19.

Pulmonary Fibrosis

Human embryonic stem cell-derived MSCs have shown promise in treating pulmonary fibrosis, as reported in Cell Proliferation. These cells may help by breaking down excess collagen, which contributes to fibrosis.

Cartilage Repair

According to findings in Transplantation and Cellular Therapy, serum-free expanded hair follicle MSCs can promote cartilage repair. This study conducted in a murine model provides insights into potential treatments for cartilage-related injuries.

Osteonecrosis

A review in Molecular Biology Reports discusses the application of MSC-derived exosomes for osteonecrosis, suggesting mechanisms of action and therapeutic strategies for reversing bone damage.

Clinical Trials

Several clinical trials are exploring the applications of MSCs:

  • Cerebral Hemorrhage Sequela (NCT02283879): Investigating the effects of umbilical cord MSCs on recovery post-cerebral hemorrhage.

  • Decompensated Liver Cirrhosis (NCT03945487): A phase 2 trial assessing MSC treatment efficacy in improving liver function in cirrhosis.

  • Osteoarthritis (NCT06082440): An early-phase trial evaluating the safety and tolerance of MSCs administered via arthroscopy for treating osteoarthritis.

  • Hereditary Ataxia (NCT01360164): This trial examines the safety and efficacy of umbilical cord MSC therapy in patients with hereditary ataxia.

  • COVID-19 (NCT04313322): Exploring MSC therapy from Wharton’s Jelly to treat COVID-19 patients, focusing on inflammation and lung damage.

In summary, MSCs are being studied for a variety of clinical applications, spanning regenerative medicine, chronic disease management, and organ-specific therapies. However, many of these applications are still in early or experimental stages, with ongoing research needed to confirm efficacy and safety.

Disclaimer: This information is for educational purposes only and not intended as medical advice. Consult healthcare professionals for medical concerns.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.